Cargando…
Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Masson SAS.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733279/ https://www.ncbi.nlm.nih.gov/pubmed/35033375 http://dx.doi.org/10.1016/j.jfo.2021.12.005 |
| _version_ | 1784627768230674432 |
|---|---|
| author | Boualila, L. Mrini, B. Tagmouti, A. El Moubarik, N. Benchekroun Belabbes, M. Boutimzine, N. Cherkaoui, L.O. |
| author_facet | Boualila, L. Mrini, B. Tagmouti, A. El Moubarik, N. Benchekroun Belabbes, M. Boutimzine, N. Cherkaoui, L.O. |
| author_sort | Boualila, L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8733279 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Masson SAS. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87332792022-01-06 Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome Boualila, L. Mrini, B. Tagmouti, A. El Moubarik, N. Benchekroun Belabbes, M. Boutimzine, N. Cherkaoui, L.O. J Fr Ophtalmol Letter to the Editor Elsevier Masson SAS. 2022-04 2022-01-06 /pmc/articles/PMC8733279/ /pubmed/35033375 http://dx.doi.org/10.1016/j.jfo.2021.12.005 Text en © 2022 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Boualila, L. Mrini, B. Tagmouti, A. El Moubarik, N. Benchekroun Belabbes, M. Boutimzine, N. Cherkaoui, L.O. Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome |
| title | Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome |
| title_full | Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome |
| title_fullStr | Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome |
| title_full_unstemmed | Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome |
| title_short | Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome |
| title_sort | sinopharm covid-19 vaccine-induced stevens–johnson syndrome |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733279/ https://www.ncbi.nlm.nih.gov/pubmed/35033375 http://dx.doi.org/10.1016/j.jfo.2021.12.005 |
| work_keys_str_mv | AT boualilal sinopharmcovid19vaccineinducedstevensjohnsonsyndrome AT mrinib sinopharmcovid19vaccineinducedstevensjohnsonsyndrome AT tagmoutia sinopharmcovid19vaccineinducedstevensjohnsonsyndrome AT elmoubarikn sinopharmcovid19vaccineinducedstevensjohnsonsyndrome AT benchekrounbelabbesm sinopharmcovid19vaccineinducedstevensjohnsonsyndrome AT boutimzinen sinopharmcovid19vaccineinducedstevensjohnsonsyndrome AT cherkaouilo sinopharmcovid19vaccineinducedstevensjohnsonsyndrome |